Bulevirtide 2 mg/day is approved in Europe, Australia, Russia, and Canada for treatment of compensated chronic hepatitis D (CHD). However, long-term outcomes after treatment discontinuation are unknown.
Journal of Hepatology published a clinical update in Research Highlights on 09 Apr 2026.
The item focuses on 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial.
Review the original article for the full source wording and details.